Ms. Otsuki has over twenty years of industry experience. Prior to Tokalas, Ms. Otsuki was founder of Selexagen Therapeutics, a discovery stage oncology company and Senior Vice President of Commercial Development at Kanisa Pharmaceuticals, Inc, an oncology development company.

She was also founder and Senior Vice President of Operations at NovaCardia, a cardiovascular specialty biopharma company which was sold to Merck for $360 million and subsequently spun its second compound into Sequel Pharmaceuticals; founder and Chief Operating Officer of DexCom (DXCM); and held several executive management level positions Quidel Corporation (QDEL), a medical diagnostics company.